Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Yes Bank 35.85 1.13
Tata Mot 160.45 1.26
State Ba 324.30 1.02
Mah & Ma 528.75 0.76
Tata Pow 51.50 0.19
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
 
Cipla Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:500087NSE:CIPLABloomberg:CIPLA@INReuters:CIPL.BO
Market Lot: 1Face Value: 2ISIN Demat: INE059A01026
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
07-Feb-2019
Business Profile
Cipla has a product range comprising antibiotics, anti-bacterials, anti-asthmatics, anthelmintics, anti-ulcerants, oncology, corticosteroids, nutritional supplements and cardiovascular drugs. It is into anti-bacterial and anti-asthmatic segments and is the first player in Asia to launch non-CFC metered dose inhaler. DPCO coverage of Cipla is around 40 per cent. Exports grew by 30 per cent, exceeding Rs l0,500 million. Both active pharmaceutical ingredients (APIs) and formulations contributed to the growth in business in the international market.

Overseas business forms 45 percent of the company`s total turnover. The company has its manufacturing facilities at Goa, Kurkumbh, Bangalore, Patalganga and Baddi. Cipla has been among the major suppliers of anti-malarial drugs and drugs for neglected diseases such as schistosomiasis to international markets. With the launch of Lamivudine, the company has become one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched).

The company plans to continue its R&D efforts with a major thrust on developing new products and delivery systems. It would also include patenting of newer processes/newer products/newer drug delivery systems/ newer medical devices/newer usage of drugs for both local and international markets. Development of agrotechnology, genetics and biotechnology for cultivation of medicinal plants and isolation of active ingredients from plant materials is also foreseen.

Financials
The company announced fall of 64.86% in consolidated net profit on y-o-y basis to Rs 1.53 billion, while total income fell 100.00% y-o-y basis to Rs 0.00 million for the quarter ended March 2018.

Recent Developments
07-FEB-19
Cipla today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (US FDA).

28-JAN-19
Cipla today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA).

12-NOV-18
Cipla today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Valganciclovir Tablets

29-OCT-18
Cipla today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Metoprolol ER Tablets 50mg, 100mg, 200mg from the United States Food and Drug Administration (US FDA).

07-AUG-18
Cipla announced that it has received final approval on August 3, 2018, for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 1% from the United States Food and Drug Administration (US FDA).

19-JUN-18
Cipla, today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Efavirenz Tablets 600mg from the United States Food and Drug Administration (US FDA).

14-JUN-18
Cipla, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, single-use sterile Ampoule from the United States Food and Drug Administration (US FDA).

08-JUN-18
Unitaid and Indian drug manufacturer Cipla struck a landmark agreement today that will lower the price of the first combination therapy (containing co-trimoxazole, isoniazid and vitamin B6) that prevents opportunistic infections in people living with HIV.



In Brief

 
Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer